10-Q: Charlies Holdings Q2 2025: Asset Sale Boosts Liquidity

Charlies Holdings, Inc. reported a significant net income for Q2 2025, driven by a $6.5 million asset sale, substantially improving its liquidity and working capital despite ongoing operational losses.

Summary

• Reported a net income of $4.961 million for the three months ended June 30, 2025, a substantial improvement from a net loss of $967,000 in the prior year period.
• Achieved a net income of $3.744 million for the six months ended June 30, 2025, compared to a net loss of $2.012 million for the same period in 2024.
• The positive financial results were primarily driven by a $6.5 million gain from the sale of PMTA (Premarket Tobacco Application) assets to R.J. Reynolds Vapor Company.
• Working capital improved significantly to $2.211 million as of June 30, 2025, from a deficit of $1.855 million at December 31, 2024.
• Cash balance increased to $1.453 million at June 30, 2025, from $211,000 at December 31, 2024.
• Product revenue for the three months ended June 30, 2025, increased by 24.5% to $2.544 million, primarily due to a $658,000 increase in sales of other alternative products distributed through Don Polly.
• Product revenue for the six months ended June 30, 2025, decreased by 4.8% to $4.850 million, mainly due to a $1.453 million decrease in sales of nicotine-based vapor products, partially offset by a $1.209 million increase in alternative product sales.
• Incurred a loss from operations of $877,000 for the three months and $1.703 million for the six months ended June 30, 2025, indicating continued operational challenges.
• Cost of goods sold increased as a percentage of revenue, reaching 73.9% for the quarter and 75.4% for the six months, reflecting lower margins on third-party brands and margin compression.
• Net cash used in operating activities increased to $3.063 million for the six months ended June 30, 2025, compared to $300,000 in the prior year period.
• Management implemented cost-cutting measures, including salary reductions of 20-50% for officers and certain managers, and a reduction in headcount.
• Launched SBX, a non-nicotine, disposable vapor product, in Q4 2024, which is believed not to be subject to FDA review.
• Continued to pursue FDA marketing authorization for its tobacco-derived and synthetic nicotine products, with an administrative appeal for certain synthetic nicotine PMTAs granted in October 2023.

Sentiment

Score: 7

Explanation: While operational losses persist and regulatory risks remain high, the significant asset sale has dramatically improved the company's liquidity and financial stability, addressing immediate going concern issues. The strategic shift towards non-nicotine products and monetization of PMTAs demonstrates proactive management and potential for future growth, outweighing the current operational challenges.

Positives

• Achieved a net income of $4.961 million for the quarter and $3.744 million for the six months ended June 30, 2025, a significant turnaround from prior year losses.
• Secured a $6.5 million gain from the sale of 15 PACHA synthetic products and related PMTA assets to R.J. Reynolds Vapor Company, with a potential contingent payment of up to $4.2 million.
• Substantially improved working capital from a deficit of $1.855 million at December 31, 2024, to a positive $2.211 million at June 30, 2025.
• Increased cash balance to $1.453 million at June 30, 2025, from $211,000 at December 31, 2024, significantly improving short-term liquidity concerns.
• Successfully repaid significant notes payable, including $1.250 million to Pinnacle and $308,000 to Ryan Stump, reducing overall debt.
• Launched the SBX non-nicotine disposable vapor product line, which is believed to be exempt from current FDA review, offering a strategic hedge against regulatory risks.
• Received FDA Acceptance Filings for over 650 PMTAs, enhancing the strategic value of its PMTA portfolio.
• Administrative appeal for certain synthetic nicotine PMTAs was granted, allowing those products to proceed in the FDA review process.
• Implemented aggressive cost-cutting measures, including salary reductions for executives and managers, and headcount reductions, to right-size the business and improve margins.

Negatives

• Experienced a 4.8% decrease in total product revenue for the six months ended June 30, 2025, primarily due to a $1.453 million decline in sales of nicotine-based vapor products.
• Continued to incur losses from operations, with $877,000 for the quarter and $1.703 million for the six months ended June 30, 2025.
• Cost of goods sold as a percentage of revenue increased, indicating margin compression, particularly from lower-margin third-party brand sales through Don Polly.
• Net cash used in operating activities significantly increased to $3.063 million for the six months ended June 30, 2025, compared to $300,000 in the prior year.
• Interest expense increased by 114.7% for the quarter and 70.2% for the six months due to higher outstanding notes payable.
• The company's financial statements continue to raise substantial doubt about its ability to continue as a going concern due to regulatory risks and industry challenges.
• Significant customer concentration, with three customers accounting for over 88% of net accounts receivable at June 30, 2025.
• Significant vendor concentration, with purchases from five vendors representing 71% of total inventory purchases for the six months ended June 30, 2025.

Risks

• Operating in a rapidly changing legal and regulatory environment, with new laws or changes to existing laws potentially limiting product sales or increasing costs.
• Uncertainty regarding FDA marketing authorization for tobacco-derived nicotine e-liquid products, with no assurance of approval and potential for Marketing Denial Orders (MDOs).
• Synthetic nicotine products are now subject to FDA rules, requiring PMTA filings and facing potential enforcement actions or MDOs.
• The FDA's regulatory initiatives and enforcement priorities regarding ENDS products are unpredictable and continue to evolve.
• Risk that Metatine-based products (SBX) could be deemed tobacco products by the FDA, requiring premarket authorization and potentially leading to enforcement actions.
• Substantial doubt about the company's ability to continue as a going concern due to regulatory risks, industry-specific challenges, and fluctuating working capital and cash position.
• No assurance that additional financing will be available on acceptable terms, or at all, to support new product development or future PMTA filings.
• If sufficient funds are unavailable, the company may be required to seek bankruptcy protection or other alternatives, potentially resulting in stockholders losing some or all of their investment.
• Customer concentration risk, with a few customers accounting for a large portion of accounts receivable.
• Vendor concentration risk, with a few vendors accounting for a large portion of inventory purchases.
• Potential for substantial costs and diversion of management resources from legal or administrative proceedings, even if not material.
• Ability to utilize Net Operating Losses (NOLs) and tax credit carryforwards may be limited by ownership changes (Sections 382 and 383 of the Code) or future regulatory changes.

Future Outlook

The company plans to increase revenues, secure cost-effective financing, and continue business development efforts, including the PMTA process. Strategic initiatives include expanding the Metatine-based SBX product line, developing new Metatine products like e-liquids and pouches by late 2025, seeking strategic partners to monetize its PMTA portfolio, and developing age-gating technology to prevent youth access. The company also aims to grow its international market share and eventually uplist to a national securities exchange to enhance market visibility and access to capital. Executive salaries are anticipated to revert to previous levels when financial circumstances improve.

Management Comments

• Our plans and growth depend on our ability to increase revenues, procure cost-effective financing, and continue our business development efforts, including the cumulative expenditures related to our premarket tobacco product application (PMTA) process of obtaining FDA approval.
• The Company has undergone cost-cutting measures including salary reductions of up to 50% for officers and certain managers and a reduction in headcount for certain departments.
• The Company may require additional financing in the future to support the development of new product categories as well as subsequent PMTA filings, and/or in the event the FDA requests additional testing for one, or several, of the Companys prior PMTA submissions.
• There can be no assurance that additional financing will be available on acceptable terms, or at all, and there can be no assurance that any such arrangement, if required or otherwise sought, would be available on terms deemed to be commercially acceptable and, in the Companys best interests.
• If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that would likely result in our stockholders losing some or all their investment in us.
• Management believes that these initiatives will enhance Charlies competitive position in the marketplace, significantly reduce costs, help accelerate the Companys path to profitability, support business growth, and, ultimately, allow the Company to achieve greater liquidity and visibility through an uplist to a national securities exchange.
• We believe adult consumers will enjoy Metatine alternative alkaloid vapor products in much the same way that they enjoy traditional vapor products.
• We believe that our substantial investments in FDA regulatory compliance make Charlies an attractive partner in this space.
• The Company believes Charlies 650+ PMTAs, as a stand-alone asset, have a monetary value that far exceeds Charlies current market cap.
• We believe age-gating is both a responsible business practice as well as a potential future competitive advantage for Charlies.

Industry Context

The company operates in a highly dynamic and challenging vapor products industry, characterized by rapid changes in laws and regulations, including potential state and municipal bans on flavored e-cigarettes and FDA initiatives to reduce nicotine levels. The industry is heavily impacted by FDA's authority over both tobacco-derived and synthetic nicotine products, requiring extensive PMTA submissions with low approval rates. In response, the company is strategically diversifying into non-nicotine alternative alkaloid products (Metatine-based SBX) as a regulatory hedge. Key competitors like JUUL Labs, Altria, and R.J. Reynolds are also investing in age-gating technologies and navigating the complex regulatory landscape, highlighting a broader industry trend towards compliance and innovation in youth access prevention.

Comparison to Industry Standards

• The company's SBX Disposables were overwhelmingly preferred over Juul tobacco-flavored vapes in a company-sponsored focus group survey, with 287 out of 306 participants preferring SBX.
• SBX products are marketed as offering more flavor options, tax advantages, and more puffs compared to mass-market vapes like Juul.
• The FDA has authorized fewer than 1% of the 26 million PMTAs for e-cigarette products and devices, with only 34 tobacco-flavored (and a handful of menthol) products approved, indicating a very stringent regulatory environment.
• The company's 650+ PMTAs for flavored vapor products remain under active FDA review, placing them among a small fraction of applications still being considered, which is seen as a significant competitive advantage given that over 80% of adults prefer flavored vapor products.
• The company's development of age-gating technology aligns with initiatives by major industry players like JUUL Labs, Altria, and R.J. Reynolds, who are also submitting PMTAs for similar mobile applications and device-locking technologies to restrict underage access.

Management Changes

Legal Proceedings

• As of the filing date, the company is not a party to any material legal or administrative proceedings.
• No proceedings involve directors, executive officers, affiliates, or stockholders as adverse parties or with material adverse interests.
• The company may be involved in various claims and legal actions in the ordinary course of business, which could result in substantial cost and diversion of resources.

Related Party Transactions

• The company entered into a two-month short-term loan agreement with its President, Henry Sicignano III, for $100,000 on February 27, 2025, which was fully repaid in April 2025.
• Unsecured promissory notes totaling $1,400,000 were issued between July 17, 2023, and August 1, 2023, to several executives and employees (Ryan Stump, Henry Sicignano III, Keith Stump, Jessica Greenwald) and largest stockholders (Brandon Stump, Red Beard Holdings LLC, Michael King).
• As of June 30, 2025, approximately $336,000 of the July 2023 Notes remained outstanding with Ryan Stump and Henry Sicignano III, with maturity extended to April 28, 2026.
• A secured promissory note for $1,000,000 was issued to Michael King (a large individual stockholder) on April 6, 2022; approximately $339,000 remained outstanding as of June 30, 2025, with maturity extended to April 28, 2026.
• A loan agreement for $300,000 was entered into with Ryan Stump (Chief Operating Officer and Director) on August 17, 2022, which was fully satisfied on April 28, 2025.
• The company leases office space in Williamsville, New York, from Henry Sicignano Jr., a relative of the President, Henry Sicignano III. Total rent paid to related parties for this lease was approximately $138,000 for both the six months ended June 30, 2025, and 2024.
• The company leases its corporate headquarters in Costa Mesa, California, from Brandon Stump (former CEO), Ryan Stump (COO), and Keith Stump (former Board member). Total rent paid to related parties for this lease is included in the $138,000 figure mentioned above.

Stakeholder Impact

• Shareholders: Experienced a significant improvement in net income and working capital due to the asset sale, potentially increasing shareholder value. However, ongoing operational losses and regulatory uncertainties pose risks to future investment returns. There is a stated risk of losing some or all investment if the company cannot continue operations.
• Employees: Officers and certain managers experienced voluntary salary reductions of 20-50%. There was a significant reduction in headcount in certain departments. Bonuses were awarded to certain key employees during the period.
• Customers: The company continues to sell synthetic nicotine products while PMTA review is ongoing, but faces the risk of product removal if FDA denies applications. The launch of SBX non-nicotine products offers new options. Customer concentration is a notable risk.
• Suppliers/Vendors: The company settled outstanding accounts payable with Chemular, Inc. and repaid Pinnacle debt. Vendor concentration is a notable risk, with a few vendors accounting for a large portion of purchases.
• Creditors: Significant repayment of notes payable, including to related parties, has improved the company's debt profile and financial position, reducing immediate credit risk.

Next Steps

• Increase revenues and procure cost-effective financing.
• Continue business development efforts, including the PMTA process for FDA approval.
• Expand the SBX Metatine-based disposable vapor product line and test-market Metatine-based e-liquids (PACHAMAMA PLUS+).
• Develop a Metatine-based pouch line, aiming for market readiness in late 2025.
• Seek strategic partners to monetize the company's PMTA portfolio.
• Continue developing intellectual property around and seeking strategic partnerships for age-gating technologies to prevent youth access to nicotine vapor products.
• Grow market share internationally, leveraging existing distribution platforms.
• Uplist from the OTCQB exchange to a national securities exchange to increase market visibility, liquidity, and access to capital.
• Revert executive base salaries to previous levels when financial circumstances permit.
• Work with the landlord to renew the Huntington Beach warehouse lease, currently operating on a month-to-month basis.

Key Dates

Recommendation

The substantial gain from the PMTA asset sale and the resulting dramatic improvement in liquidity and working capital are significant positives, addressing immediate going concern concerns. However, the company continues to face operational losses, declining revenue in its core nicotine products, and high regulatory uncertainty in the vapor industry. The strategic shift to Metatine-based products and monetization of PMTAs offers potential upside, but their commercial success and long-term regulatory status are unproven. Given this mixed financial performance and the persistent high regulatory risk, a 'Hold' recommendation is appropriate, suggesting investors monitor the execution of strategic initiatives and regulatory developments closely before making further investment decisions.

Keywords

Vapor products, E-cigarettes, Nicotine, Synthetic nicotine, Metatine, FDA regulation, PMTA, Premarket Tobacco Application, SBX, Pacha, Financial results, Quarterly report, Liquidity, Working capital, Asset sale, Regulatory compliance, Age-gating technology, OTCBB, CHUC